| Name | Title | Contact Details |
|---|
Herspiegel is a consulting firm based in Pennsylvania, founded in 2007, that specializes in pharmaceutical and biotech commercialization services. With over fifteen years of experience, the company has supported more than 150 product launches across various therapeutic areas, including primary care, oncology, and rare diseases. Their mission is to create a model for successful pharmaceutical product launches. The firm offers a wide range of services tailored to the life sciences industry, including market access, medical affairs, marketing strategy, and operational execution. Herspiegels team consists of over 350 experts, including MDs, PhDs, MBAs, and pharmacists, who provide deep knowledge to help clients navigate complex challenges and maximize brand potential. They serve a diverse clientele, from startups to large global pharmaceutical companies, focusing on strategic insights and operational excellence to enhance commercial success and patient outcomes. Herspiegel has also expanded its capabilities through strategic acquisitions, such as Decisive Consulting, which enhances their market access and value strategy services. This positions Herspiegel to deliver innovative solutions in a dynamic pharmaceutical landscape.
We are a full-service agency providing insurance in personal, business, bonding, farm, life, and flood. Our staff has over 400 years of experience. We pride ourselves on customer service and knowledge of the products we offer. Stop in to one of our North Dakota or Minnesota locations.
First Pacific Bank is a growing community bank catering to individuals, professionals, and small-to-medium sized businesses throughout Southern California. With a history that spans 17 years, the bank offers a personalized approach, access to decision makers, a broad range of solutions, and a commitment to delivering an exceptional customer experience. First Pacific Bank operates locations in Los Angeles County, Orange County, San Diego County, and the Inland Empire. For more information, visit firstpacbank.com or call 562.947.1920.
CNH Industrial N.V. is a global manufacturer of agricultural and construction equipment, headquartered in Basildon, Essex, United Kingdom. The company has a rich history dating back to 1842 and was formed through the merger of Case Corporation and New Holland N.V. in 1999, later restructuring as CNH Industrial in 2013. With over 63,000 employees, CNH operates 67 manufacturing plants and 56 research and development centers across 180 countries. The company offers a wide range of products under well-known brands such as Case IH, New Holland Agriculture, and Case Construction Equipment. Their agricultural equipment includes tractors, combines, and precision farming technology, while their construction equipment features excavators, backhoe loaders, and dozers. CNH also provides financial services through CNH Industrial Capital, supporting customers with equipment financing and offering integrated engineering and aftermarket support. The company is committed to sustainable technologies, including precision agriculture and alternate fuel solutions.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.